| Stage | CBT | % of rev | FTK | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $982M | 100.00% | $99M | 100.00% | CBT ×9.88 |
| Gross profit | $184M | 18.74% | $24M | 23.93% | FTK +5.2pp |
| Operating income | $98M | 9.98% | $15M | 14.98% | FTK +5.0pp |
| Pre-tax income | $58M | 5.91% | $14M | 13.62% | FTK +7.7pp |
| Net income | $14M | 1.43% | $10M | 10.02% | FTK +8.6pp |
| Stage | CBT | FTK | Gap · A − B |
|---|---|---|---|
| Revenue | $982M100.00% | $99M100.00% | CBT ×9.88 |
| Gross profit | 18.74%$184M | 23.93%$24M | FTK +5.2pp |
| Operating income | 9.98%$98M | 14.98%$15M | FTK +5.0pp |
| Pre-tax income | 5.91%$58M | 13.62%$14M | FTK +7.7pp |
| Net income |
| 1.43%$14M |
| 10.02%$10M |
| FTK +8.6pp |
None
No disclosed counterparties: CBT.